Centogene (CNTG) announced the extension of an ongoing partnership with Takeda (TAK) to diagnose patients with Lysosomal Storage Disorders. Under the renewed agreement, Centogene will continue to provide Takeda with access to diagnostic testing for patients around the world. The agreement was established to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNTG:
- CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
- Centogene receives Nasdaq notice of delisting, will request hearing
- CENTOGENE Explores Strategic Alternatives
- CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
- Centogene to explore a range of strategic alternatives